Glioblastoma (GBM) is the most common and highly aggressive primary brain tumor in adults. MicroRNAs (miRNAs) are pleiotropic post-transcriptional regulators of oncogenic pathways, and frequently lose their tumor-suppressive function in GBM. Researchers from the Istituto Italiano di Tecnologia previously identified a group of 11 pro-neurogenic miRNAs that supports adult neurogenesis by jointly regulating multiple targets in mouse neural stem cells. Writing in Molecular Therapy Nucleic Acids, they present a study where they examined the expression of these 11 miRNAs across glioma grades and GBM subtypes in patients.
Australian researchers have found a drug combination that can bypass the cellular defenses in neuroblastoma that lead to relapse, and the discovery could lead to better treatment strategies for children whose cancers have stopped responding to standard chemotherapy.
Australian researchers have found a drug combination that can bypass the cellular defenses in neuroblastoma that lead to relapse, and the discovery could lead to better treatment strategies for children whose cancers have stopped responding to standard chemotherapy.
Treatment in glioblastoma usually fails due to tumor heterogeneity and persistence of glioblastoma multiforme stem-like cells (GSCs) within the tumor margin. Researchers from Trogenix Ltd. engineered TGX-007, an AAV1-mediated therapeutic that delivers both cytotoxic and immunomodulatory genetic payloads to the tumor.
Shanghai Apeiron Biotechnology Co. Ltd. has divulged protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of brain metastatic cancer.
Sunrise Oncology (Hong Kong) Ltd. has identified molecular glues acting as phosphodiesterase PDE3A/SLFN12 interaction inducers reported to be useful for the treatment of cancer.
In glioblastoma multiforme, MTAP loss leads to MTA accumulation, which partially inhibits PRMT5, making the cells reliant on residual PRMT5 activity for survival. Targeting this remaining PRMT5 with MTA-cooperative inhibitors induces synthetic lethality, representing a promising targeted approach for MTAP-deleted gliomas. Researchers from Ryvu Therapeutics SA reported the preclinical profile of RVU-305, a PRMT5 inhibitor, in MTAP-deleted cancer models.
